Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

With the growing demand for weight-loss solutions, many individuals in India have resorted to purchasing obesity drugs from ...

Lilly isn't alone in this, Danish drugmaker Novo Nordisk - which markets blockbuster weight loss drug Ozempic - too had ...

Dr. Alexandra Sowa discusses the risks and benefits of using popular weight loss drugs like Ozempic and Wegovy. Sowa says the ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...